EUVIMEDEUVIMED entdecken
Crossref

ATP‐Citrate Lyase: A Prognostic Marker of Non‐Small Cell Lung Cancer Dictates the Progression of Adenocarcinoma in Indian Population

Kanika Phutela, Navneet Singh, Amanjit Bal, Harkant Singh, Jyotdeep Kaur, Sadhna Sharma

Cell Biochemistry and Function · 2025

DOI: 10.1002/cbf.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biochemistry and Function, 2025. Verfasst von Kanika Phutela und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: ATP Citrate (pro-S)-Lyase, Biomarkers, Tumor, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tissue biopsies are routinely used for identifying driver mutations in tumors but limitations such as tumor heterogeneity have encouraged the use of liquid biopsies for the identification of new biomarkers. ATP‐citrate lyase (ACLY) has been recognized as a potential target for tumor inhibition due to its overexpression in several cancers. However, the clinical significance of this enzyme remains unknown in liquid biopsies. In this study, 31 pleural effusion fluid samples were collected from patients suspected of malignancy for analyzing the gene expression of ACLY and associated metabolic enzymes. Gene expression profiling by RT‐PCR revealed significantly increased ACLY mRNA levels along with other metabolic enzymes (FASN, ACC, CS, and ICD1) in malignant lung adenocarcinoma pleural fluid samples indicating that ACLY plays a critical role in the progression of lung adenocarcinoma. This study identified the potential of using metabolic enzymes as biomarkers in identification of lung adenocarcinoma patients. The observations highlighted the significance of lipogenic enzymes mainly ACLY and fatty acid synthase as diagnostic markers in lung adenocarcinoma liquid biopsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Citrate (pro-S)-LyaseBiomarkers, TumorLung NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinoma of LungAdenocarcinomaHumansMaleFemaleMiddle AgedPrognosisIndiaDisease ProgressionAgedAdult

Stichwörter der Autor:innen

ATP‐citrate lyasefatty acid synthaselung adenocarcinomanon‐small cell lung cancerpleural effusion

Substanzen

ATP Citrate (pro-S)-LyaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Zitieren

APA

Phutela, K., Singh, N., Bal, A., Singh, H., Kaur, J., & Sharma, S. (2025). ATP‐Citrate Lyase: A Prognostic Marker of Non‐Small Cell Lung Cancer Dictates the Progression of Adenocarcinoma in Indian Population. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70109

Vancouver

Phutela K, Singh N, Bal A, Singh H, Kaur J, Sharma S. ATP‐Citrate Lyase: A Prognostic Marker of Non‐Small Cell Lung Cancer Dictates the Progression of Adenocarcinoma in Indian Population. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70109

BibTeX
@article{Phutela2025,
  author = {Phutela, Kanika and Singh, Navneet and Bal, Amanjit and Singh, Harkant and Kaur, Jyotdeep and Sharma, Sadhna},
  title = {ATP‐Citrate Lyase: A Prognostic Marker of Non‐Small Cell Lung Cancer Dictates the Progression of Adenocarcinoma in Indian Population},
  journal = {Cell Biochemistry and Function},
  year = {2025},
  doi = {10.1002/cbf.70109}
}
Kostenlos starten →